Defining an optimal time window to screen for hepatoblastoma in children with Beckwith‐Wiedemann syndrome. Issue 1 (30th September 2018)

• Record Type: Journal Article
• Authors: Mussa, Alessandro; Duffy, Kelly A.; Carli, Diana; Ferrero, Giovanni Battista; Kalish, Jennifer M.
• Is Part Of: Pediatric blood & cancer. Volume 66:Issue 1(2019)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2018-09-30
• Subjects: alpha‐fetoprotein -- Beckwith‐Wiedemann -- cancer screening -- hepatoblastoma; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.27492
• Languages: English
• ISSNs: 1545-5009

Abstract

Abstract: Patients with Beckwith‐Wiedemann spectrum (BWSp) undergo quarterly alpha‐fetoprotein measurement for hepatoblastoma (HB) screening up to 4 years of age, paralleling the epidemiology of nonsyndromic HB. However, specific data on the timing of HB development in BWSp are lacking. Here we compare the timing of presentation of HBs in BWSp with a control cohort of consecutive HB cases, demonstrating that halving screening duration of screening procedures in BWSp likely will not impact its effectiveness.